BioSpace News Archive

Sientra, Inc. (Nasdaq: SIEN), a medical aesthetics company, announced today that it will release 4Q19 financial results after the close of trading on Wednesday, March 11, 2020.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the fourth quarter and full-year ended December 31, 2019.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today financial results for the three-months and full-year ended December 31, 2019 and reaffirmed revenue guidance for 2020.

CPhI Japan – organised by Informa Markets – announces that the event will be postponed until a new date later in the year after extensive consultation with key stakeholders and consideration of all alternatives.

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that management will present at the Cowen 40th Annual Health Care Conference on Wednesday, March 4th, 2020 at 10:00 am ET.

Atrion Corporation announced that for the fourth quarter of 2019 revenues were $34.5 million compared to $34.9 million in the same period of 2018, net income was $8.1 million compared to $7.7 million in the prior year period, and diluted earnings per share were $4.33 compared to $4.17 in the prior-year period.

Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today highlighted the publication of an article describing the anti-epileptic and anti-convulsive activity of betahistine in a mouse model.

Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will webcast management presentations as follows

Mesoblast Limited reported financial, corporate and operational highlights for the half year ended December 31, 2019.

U.S. FDA Grants Investigational New Drug Authorization to Study Remdesivir for the Treatment of COVID-19